Trials / Not Yet Recruiting
Not Yet RecruitingNCT06712771
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 Injection in Chinese Adolescents and Adults with Homozygous Familial Hypercholesterolaemia (HoFH)
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Visirna Therapeutics HK Limited · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Significant reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead to the reduction of risk of coronary heart disease and cardiovascular events associated with hypertriglyceridemia and LDL-C in subjects with persistent dyslipidemia. In this clinical study, the efficacy and safety of VSA003, an RNAi-based therapeutic targeting ANGPTL3, will be evaluated in subjects with HoFH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VSA003 | subcutaneous injections |
| DRUG | Placebo | subcutaneous injections |
Timeline
- Start date
- 2024-12-02
- Primary completion
- 2026-06-30
- Completion
- 2027-12-30
- First posted
- 2024-12-02
- Last updated
- 2024-12-02
Source: ClinicalTrials.gov record NCT06712771. Inclusion in this directory is not an endorsement.